Rosetta Genomics Announces Sponsored Research Agreement With Ramot at Tel Aviv University

Rosetta Genomics Announces Sponsored Research Agreement With Ramot at Tel Aviv 
University 
Joint Development of Nano-Carrier Delivery System for miR Mimetic
Technology to Treat Cancer to Be Partially Funded by Israel's Office
of the Chief Scientist 
PRINCETON, NJ and REHOVOT and TEL AVIV, ISRAEL -- (Marketwired) --
10/31/13 --   Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading
developer and provider of microRNA-based molecular diagnostics,
announces that the Company has entered into a sponsored research
agreement with Ramot at Tel Aviv University (Ramot), a Company
organized under the laws of Israel and a wholly-owned subsidiary of
Tel Aviv University (TAU), for the joint development of a
nano-carrier system for miR mimetic technology to treat cancer.  
Dr. Sharon Kredo-Russo, Associate Director, R&D of Rosetta Genomics
and Rosetta's scientists, together with Prof. Ronit Satchi-Fainaro,
Department of Physiology and Pharmacology, Sackler School of
Medicine, Tel Aviv University and members of her research team at
TAU, jointly developed technology relating to a nano-carrier deliver
system with a miRNA mimetic. This unique system can significantly
enhance the stability, intracellular trafficking and efficacy of the
miRNA.  
The parties will perform joint research under the Magneton Project
administered by the Office of the Chief Scientist of the Ministry of
Economics (OCS) for an initial period of 12 months commencing on
October 1, 2013 and an additional period of 12 months, subject to
approval by OCS. Rosetta Genomics has already received initial
approval from the OCS for the Magneton Project. The results of the
joint research project will be jointly-owned by Rosetta Genomics and
Ramot. Rosetta Genomics will fund the research to be performed by
Prof. Ronit Satchi-Fainaro at Tel Aviv University in the amount of
242,460 NIS in accordance with an agreed upon payment schedule and
subject to receipt of the OCS funding.  
"We are delighted the OCS has determined to fund this important
project. This research collaboration represents a cost-effective and
efficient way for us to expand our footprint into cancer therapeutics
by leveraging the Company's valuable microRNA intellectual property,"
said Kenneth A. Berlin, President of Rosetta Genomics. "Ramot is an
excellent partner for this project and Prof. Satchi-Fainaro is a
well-regarded expert in the field of cancer and microRNA
nanomedicines as she is known for her cutting edge research. We look
forward to advancing this collaboration to develop what we hope will
be effective new cancer treatments." 
"The growing understanding of the importance of microRNAs has
generated intense activity in the biomedical research community.
Rosetta has been at the forefront of this scientific revolution. Our
goal is to leverage our broad-based patent position in microRNA
technology to bring innovative new diagnostics and therapies to
patients in need, while creating new revenue sources for the Company.
In addition to oncology, we are pursuing this strategy in infectious,
immune-mediated and cardiovascular diseases," concluded Mr. Berlin.  
About Rosetta Cancer Testing Services 
 Rosetta Cancer Tests are a
series of microRNA-based diagnostic testing services offered by
Rosetta Genomics. The Rosetta Cancer Origin Test(TM) can accurately
identify the primary tumor type in primary and metastatic cancer
including cancer of unknown or uncertain primary (CUP). The Rosetta
Mesothelioma Test(TM) diagnoses mesothelioma, a cancer connected to
asbestos exposure. The Rosetta Lung Cancer Test(TM) accurately
identifies the four main subtypes of lung cancer using small amounts
of tumor cells. The Rosetta Kidney Cancer Test(TM) accurately
classifies the four most common kidney tumors: clear cell renal cell
carcinoma (RCC), papillary RCC, chromophobe RCC and the benign
oncocytoma. Rosetta's assays are designed to provide objective
diagnostic data; it is the treating physician's responsibility to
diagnose and administer the appropriate treatment. In the U.S. alone,
Rosetta Genomics estimates that 200,000 patients a year may benefit
from the Cancer Origin Test, 60,000 from the Mesothelioma Test,
65,000 from the Kidney Cancer Test and 226,000 patients from the Lung
Cancer Test. The Company's assays are offered directly by Rosetta
Genomics in the U.S., and through distributors around the world. For
more information, please visit www.rosettagenomics.com. Parties
interested in ordering the test can contact Rosetta Genomics at (215)
382-9000 ext. 309. 
About Rosetta Genomics
 Rosetta develops and commercializes a full
range of microRNA-based molecular diagnostics. Founded in 2000,
Rosetta's integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building on
its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the
development and commercialization of a full range of microRNA-based
diagnostic tools. Rosetta's cancer testing services are commercially
available through its Philadelphia-based CAP-accredited,
CLIA-certified lab. Frost & Sullivan recognized Rosetta Genomics with
the 2012 North American Next Generation Diagnostics Entrepreneurial
Company of the Year Award. 
About Ramot at Tel Aviv University 
 Ramot is the technology transfer
company of Tel Aviv University. Ramot fosters, initiates, leads and
manages the transfer of new technologies from university laboratories
to the marketplace by performing all activities relating to the
protection and commercialization of inventions and discoveries made
by faculty, students and other researchers. Ramot provides a dynamic
interface connecting industry to leading-edge science and innovation,
offering new business opportunities in a broad range of emerging
markets.  
For more information, visit www.ramot.org. 
Forward-Looking Statement Disclaimer
 Various statements in this
release concerning Rosetta's future expectations, plans and
prospects, including without limitation, Rosetta's Cancer of Origin
Test, the Cancer Origin Test improving the ability of physicians to
accurately diagnose CUP, the Cancer Origin Test's ability to help
physicians to optimize treatment, Rosetta's development or
commercialization of molecular diagnostics, the market acceptance of
Rosetta's cancer testing services, particularly the Cancer Origin
Test, the joint research with Ramot and Tel Aviv university leading
to results and the development of microRNA based therapeutics,
constitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform Act
of 1995. Actual results may differ materially from those indicated by
these forward-looking statements as a result of various important
factors, including those risks more fully discussed in the "Risk
Factors" section of Rosetta's Annual Report on Form 20-F for the year
ended December 31, 2012 as filed with the SEC. In addition, any
forward-looking statements represent Rosetta's views only as of the
date of this release and should not be relied upon as representing
its views as of any subsequent date. Rosetta does not assume any
obligation to update any forward-looking statements unless required
by law. 
Company Contact: 
Rosetta Genomics 
Ken Berlin
President & CEO 
(609) 419-9000, ext. 1326 
investors@rosettagenomics.com 
Company Contact: 
Dr Tamar Raz 
VP Strategy & Marketing, 
RAMOT at Tel Aviv University Ltd. 
E. tamar@ramot.org 
P. +972.3.6406580 
Investor Contacts: 
LHA 
Anne Marie Fields
(212) 838-3777
afields@lhai.com 
or 
Bruce Voss
(310) 691-7100
bvoss@lhai.com 
 
 
Press spacebar to pause and continue. Press esc to stop.